U.O. Oncologia Medica 2 Universitaria
Welcome,         Profile    Billing    Logout  
 3 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Masi, Gianluca
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting
3
200
Europe, US, RoW
Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma
05/26
08/26
HAITI, NCT06332079: Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients

Recruiting
2
46
Europe
166Holmium TARE, Cetuximab, Panitumumab, 5-Fluorouracil, Bevacizumab, Capecitabine
Gruppo Oncologico del Nord-Ovest
Colorectal Cancer Metastatic
11/26
02/27
TriComB, NCT04564898: Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients.

Active, not recruiting
1/2
48
Europe
Capecitabine, Bevacizumab, Trifluridine/Tipiracil
Gruppo Oncologico del Nord-Ovest
Colorectal Cancer Metastatic
12/24
03/25
NCT05630937 / 2020-001002-26: Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy

Completed
1/2
31
Europe, US
NMS-01940153E
Nerviano Medical Sciences
Unresectable Hepatocellular Carcinoma (HCC)
01/24
08/24
NCT05301465: Predictive Role of Circulating Angiogenic Factors for Second-line Paclitaxel and Ramucirumab.

Recruiting
N/A
50
Europe
University of Pisa
Gastric Cancer Stage IV
11/22
06/23
Vivaldi, Caterina
ASPIRE, NCT05254171: Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

Recruiting
2/3
600
Europe, US, RoW
SBP-101, ivospemin, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar, Placebo
Panbela Therapeutics, Inc.
Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
08/26
01/27
Fornaro, Lorenzo
PURITY, NCT06037980: CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence

Recruiting
2/3
300
Europe
Gemcitabine, Nab paclitaxel, Abraxane, Cisplatin, Curative Surgery, Capecitabine
Gruppo Oncologico del Nord-Ovest
Biliary Tract Cancer, Cholangiocarcinoma
12/28
01/29
ROME, NCT04591431 / 2018-002190-21: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Active, not recruiting
2
400
Europe
Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs, Pralsetinib, Selpercatinib, Talazoparib, Tepotinib, Alpelisib
Fondazione per la Medicina Personalizzata
Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
12/24
06/25

Download Options